India-based firm Lupin has joined the pegfilgrastim parade with the FDA’s approval of Armlupeg (pegfilgrastim-unne), the seventh biosimilar for Amgen’s Neulasta approved in the US since 2018. Like ...
Global pharma major Lupin Limited (Lupin), announced that the United States Food and Drug Administration (FDA) has approved Armlupeg (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in ...
Data demonstrate a high degree of similarity between Armlupeg and the reference product. The Food and Drug Administration (FDA) has approved Armlupeg ™ (pegfilgrastim-unne), a biosimilar to Neulasta ® ...
Armlupeg, a biosimilar to Neulasta, is approved for reducing febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. Lupin's FDA-approved facility in India ...
The drug decreases the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Nilesh Gupta, MD, Lupin, ...
Warner Bros. Discovery recently fixed a silly mistake and put the “HBO” back in Max. Unfortunately a return to the site’s old name hasn’t stopped it’s owner from pulling the same old crap. Last year ...
Waking up early on a Saturday morning just so we could catch our favorite cartoon tune in on time had its own charm back in the day. There was nothing like indulging in those few glorious hours of ...
Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other medications, ...
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback